FY2030 Earnings Forecast for PTGX Issued By HC Wainwright

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Stock analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Protagonist Therapeutics in a research note issued on Friday, January 30th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of $5.40 for the year. HC Wainwright has a “Buy” rating and a $117.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The firm had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%.

A number of other research firms have also issued reports on PTGX. Johnson Rice set a $112.00 target price on shares of Protagonist Therapeutics in a report on Monday, October 13th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, October 13th. Citigroup raised their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Citizens Jmp boosted their target price on Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Jefferies Financial Group increased their price target on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $91.64.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $83.05 on Monday. The business has a fifty day moving average price of $86.17 and a 200 day moving average price of $73.13. The company has a market cap of $5.19 billion, a P/E ratio of 133.95 and a beta of 2.26. Protagonist Therapeutics has a one year low of $33.70 and a one year high of $96.54.

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors have recently bought and sold shares of PTGX. Farther Finance Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at approximately $27,000. Bessemer Group Inc. grew its stake in shares of Protagonist Therapeutics by 171.0% in the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after acquiring an additional 318 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in shares of Protagonist Therapeutics during the third quarter worth $29,000. Finally, CWM LLC boosted its holdings in Protagonist Therapeutics by 201.5% in the second quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after purchasing an additional 407 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CFO Asif Ali sold 46,203 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the sale, the chief financial officer directly owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. The trade was a 43.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $82.42, for a total value of $1,083,905.42. Following the completion of the sale, the insider owned 84,115 shares in the company, valued at $6,932,758.30. This represents a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 165,167 shares of company stock valued at $13,732,039 over the last 90 days. 4.90% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.